All Search Results
News Releases
Nov 05, 2025, 10:31 ET Hyaluronic Acid Products Market to Reach $20 billion, Globally, by 2034 at 7.7% CAGR: Allied Market Research
Market by Product Type (Hyaluronic Acid Injections, Hyaluronic Acid Eye Drops, and Others), Application (Aesthetics and Dermatology, Orthopedics, Ophthalmology, and Others), and End User (Hospitals, Specialty Clinics, and Others): Global Opportunity Analysis and Industry Forecast, 2025-2034". According
More news about: Allied Market Research
Nov 05, 2025, 07:57 ET Simple Solution Remains Out of Reach for Women: Glasses
Ophthalmology, shows that women are less likely to receive this kind of straightforward vision care, especially in Southeast Asia, East Asia, and Oceania,
More news about: Orbis International
Nov 05, 2025, 07:00 ET Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)
therapeutic landscape by becoming a safe, first-line unifying therapy for all causes of MESI." "At the recent American Academy of Ophthalmology meetings, intraocular interleukin-6 inhibition was shown in Phase 3 clinical trials to deliver a meaningful improvement in vision and anatomy in
More news about: Kodiak Sciences Inc.
Nov 05, 2025, 07:00 ET InMode Reports Third Quarter 2025 Financial Results: Quarterly Revenue of $93.2 Million, 78% Gross Margins
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.
More news about: InMode Ltd.
Nov 04, 2025, 19:00 ET Multiple Research Results from Innovent's General Biomedicine Pipeline Showcased at 2025 ACR Annual Meeting
that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announced that pre-clinical study results of IBI3011 (IL-1RAP monoclonal antibody) and IBI3034 (TACI/BCMA chimeric
More news about: Innovent Biologics